Instructor
American University in cairo
Total years of experience :30 years, 10 Months
AUC instructor, School of Business, Executives Education
Instructional design and development of pharmaceutical marketing certificate program launched in October 2021
CEO, Kahira pharmaceuticals and chemical industries
Leading a full fledge enterprise with 2200 employees including a pharmaceutical manufacturing site
Board member in Arab Medical Packing Company (Flexi Pack) representing EGYDRUG holding company
• Responsibility of NTS ex-source, In-market sales follow, Portifolio management and profitability
• Development of high potential staff & second line leaders.
• Keeping an excellent company Image within the key customers
• Compliance with J&J guidelines and local laws & regulations
• Role model in credo values.
Job profile can be further discussed
Resposnible for Immunology Portifolio (Remicade, Simponi & Stelara) and Internal Medicine (Pariet, Resolor and Invokana)
Managing a business worth of 46 Mio Euros with growth of 20% versus 2012
Direct reports: 5 Sales Managers, 2 Country Value Team Leaders (CVTL) & 3 Product Managers
Total Head count of the unit: 74 FTE
- Transition head of acquired business worth of 25 Mio $ across GCC countries by leading a multiple function heads responsible for 8 business processes.
- Setting up a new business unit from scratch (sales, marketing, reps)
- Distributor contracts negotiation and Due diligence responsibility
- Member in Emerging markets immunology leadership team
Responsible for sales (in-market and ex-source / P&L), marketing and people management of Neurology Business Unit, Saudi Arabia
Marketing responsibility covers GCC
Direct reports: 1 Sales Manager, 1 Franchise Manager as well as 1 Product Manager
Medical reps: 13 reps
Regional marketing responsibility for highly diversified markets by leading a team of 3 product managers responsible for marketing Biotech, Oncology, HIV and narcotic analgesia products in the GCC countries through:
-Developing in-depth knowledge with key oncologists, oncology pharmacists, purchasers, and stock controllers in relation to the franchise under responsibility in different countries.
-Obtaining and analysis of information from different markets, and market research to define current and future needs.
-Identification and assessment of critical success factors, growth drivers and barriers of the products under responsibility.
-Analysis of internal information from sales reports and representatives.
-Developing marketing plans including SWOT analysis, strategies, tactics, and promotional campaigns and materials based on local needs.
-Budget control of multiple products and of different countries .
-Market, Product, and Competitor analysis.
-Effective communication, training and field force support.
-Planned and implemented the pre-launch activities for Velcade® for patients with refractory and relapsed Multiple Myeloma through:
-Market research to identify market potential, trends, treatments evolutions, target customers followed by establishment of centres mapping.
-SWOT analysis and identification and assessment of CSF and growth drivers
-Development and implementation of marketing plans and promotional materials by visit
-Regional field force training camps and update.
-Regional Middle East West Asia Oncology Standalone meeting, Rome, March 2005
Key projects:
-Develop creative projects to add value to customers
-Key opinion leaders' development:
Responsible for all marketing activities of this highly specialised franchise (promoting Eprex®, erythropoietin alpha for cancer related anaemia, and Durogesic® TTS opioid analgesic for cancer pain and recently Velcade® for relapsed refractory multiple Myeloma.)
Responsible for all marketing activities of this highly specialised franchise promoting Eprex®, erythropoietin alpha for cancer related anaemia, and Durogesic® TTS opioid analgesic for cancer pain and recently Velcade® for relapsed refractory multiple Myeloma.
Job description summary includes:
Regional marketing responsibility for a highly diversified markets through:
-Developing in-depth knowledge with key oncologists, oncology pharmacists, purchasers, and stock controllers in relation to the franchise under responsibility in different countries.
- Obtaining and analysis of information from different markets, and market research to define current and future needs.
-Identification and assessment of critical success factors, growth drivers and barriers of the products under responsibilty.
- Analysis of internal information from sales reports and representatives.
-Developing marketing plans including SWOT analysis, strategies, tactics, and promotional campaigns and materials based on local needs.
-Budget control of multiple products and of different countries .
-Market, Product, and Competitor analysis.
-Effective communication, training and field force support.
-Planned and implemented the pre-launch activities for Velcade® for patients with refractory and relapsed Multiple Myeloma through:
-Market research to identify market potential, trends, treatments evolutions, target customers followed by establishment of centers mapping.
-SWOT analysis and identification and assessment of CSF and growth drivers
-Development and implementation of marketing plans and promotional materials by visit
-Regional field force training camps and update.
-Regional MEWA Onc. Standalone meeting, Rome, March 2005
Responsible for all marketing activities of this newly formed highly specialised franchise promoting Eprex®, erythropoietin alpha for cancer related anaemia, and Durogesic® TTS opioid analgesic for cancer pain .
(Job responsibilities and activities as mentioned above.)
Responsible for all Pre-Marketing activities, marketing, launch, and training for all new products ( Muse for erectile dysfunction, Durogesic TTS analgesic patches for cancer patients, and Topamax, new generation anti- epileptic )
Launching Durogesic, a transdermal patches for cancer pain
Launching Cilest, a new generation of oral contraceptives
Responsible for marketing activities related to anti-fungals franchise including Sporanox, Nizoral cream, Dacktrin cream.
Launching Sporanox one week pulse (new regimen)
Mar 1995 - Dec 1996
Managing EZ institution business for all brands including deals with big customers, and hospitals.
Apr 1994 - Feb 1995
Responsible for detailing Prepulsid, Hismanal, and Gyno-Daktrin in King Faisal Specialist Hospital, Security Forces Hospital, King Khaled University Hospital
Responsible for detailing Prepulsid, Nizoral tab., Hismanal, and Gyno dacktrin
he INSEAD Blue Ocean Strategy Program is based on the concept tools and frameworks of Blue Ocean Strategy developed by INSEAD professors W. Chan Kim & Renée Mauborgne. It offers executives insight into the concept, tools, and methodologies necessary to break out of the red ocean of competition and create a blue ocean of uncontested market space. Blue ocean strategy is not about how to compete, but about how to make the competition irrelevant by simultaneously pursuing differentiation and low costs.
Bachelor of pharmacy
from KG to secondary education French language study from KG